title: Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
abstract: BACKGROUND
  The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-β (Aβ)1-42/Aβ1-40 ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD.
  
  
  METHODS
  CSF levels of Aβ1-40 and Aβ1-42 in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays.
  
  
  RESULTS
  The CSF Aβ1-42/Aβ1-40 ratio increased discrimination of AD from PDD and DLB compared with either of the two Aβ biomarkers individually.
  
  
  CONCLUSIONS
  The use of the Aβ1-42/Aβ1-40 ratio could improve the differentiation of AD from PDD and DLB.
authors.affiliation: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden. magdalena.nutu@neuro.gu.se
authors.forename: Magdalena
authors.initials: M
authors.lastname: Nutu
authors.forename: Henrik
authors.initials: H
authors.lastname: Zetterberg
authors.forename: Elisabet
authors.initials: E
authors.lastname: Londos
authors.forename: Lennart
authors.initials: L
authors.lastname: Minthon
authors.forename: Katarina
authors.initials: K
authors.lastname: Nägga
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.forename: Oskar
authors.initials: O
authors.lastname: Hansson
authors.forename: Annika
authors.initials: A
authors.lastname: Ohrfelt
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid* / Q000276:immunology; D000906:Antibodies / Q000276:immunology; D019540:Area Under Curve; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003704:Dementia / Q000134:cerebrospinal fluid*; D003937:Diagnosis, Differential; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D020961:Lewy Body Disease / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid; D010446:Peptide Fragments / Q000134:cerebrospinal fluid* / Q000276:immunology; D011569:Psychiatric Status Rating Scales
chemical_list: D016229:Amyloid beta-Peptides; D000906:Antibodies; D015415:Biomarkers; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42)